Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

Technology appraisal guidance
Reference number: TA329
Published: 25 February 2015

History

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line) [ID695]: equality impact assessment - guidance review

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line) [ID695]: equality impact assessment - guidance review (PDF 181 KB)

Published:

05 March 2015

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line) [ID695]: final appraisal determination

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line) [ID695]: final matrix

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line): final matrix (PDF 94 KB)

Published:

22 November 2013

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line) [ID695]: Guidance consultation

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line) [ID695]: Guidance consultation
Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line) [ID695]: Evaluation report part1 information
Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line) [ID695]: Evaluation report part1 (PDF 9.41 MB)

Published:

24 September 2014
Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line) [ID695]: Evaluation report part2 information
Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line) [ID695]: Evaluation report part2 (PDF 10.06 MB)

Published:

23 September 2014
Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line) [ID695]: appraisal consultation document information

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line): assessment report consultation

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line): assessment report consultation (PDF 4.3 MB)

Published:

15 July 2014

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line): final protocol

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line): final protocol (PDF 451 KB)

Published:

13 December 2013

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line): final scope

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line): final scope (PDF 103 KB)

Published:

19 November 2013

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line): response to consultee and commentator comments on the provisional matrix (post-referral)

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line): response to consultee and commentator comments on the provisional matrix (post-referral) (PDF 70 KB)

Published:

22 November 2013

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line): response to consultee and commentator comments on the draft scope (post-referral)

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line): response to consultee and commentator comments on the draft scope (post-referral) (PDF 155 KB)

Published:

22 November 2013

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line): final matrix

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line): final matrix (PDF 94 KB)

Published:

22 November 2013

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line): Equality Impact Assessment - scoping

Ulcerative colitis (moderate, severe) - infliximab (review TA140), adalimumab (review TA262) & golimumab (2nd line): Equality Impact Assessment - scoping (PDF 122 KB)

Published:

22 November 2013

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) [ID695]: provisional matrix

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) [ID695]: provisional matrix (PDF 98 KB)

Published:

08 August 2013

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) [ID695]: draft scope

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) [ID695]: draft scope (PDF 106 KB)

Published:

08 August 2013